Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nanobiotix S.A. ADR
(NQ:
NBTX
)
5.280
+0.350 (+7.10%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nanobiotix S.A. ADR
< Previous
1
2
3
4
5
Next >
Voting Rights and Shares Capital of the Company
August 08, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
July 09, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
June 12, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
June 11, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
June 02, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
May 28, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
May 23, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
May 22, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
May 21, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
May 16, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
May 15, 2024
Conference call and webcast scheduled on May 22, 2024, at 8:00 am EDT / 2:00 pm CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
May 14, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
April 24, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
April 17, 2024
Conference call and webcast scheduled for Thursday, April 25, 2024, at 8:00 am EDT / 2:00 pm. CEST
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
April 10, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
April 02, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Present at Upcoming Investor Conferences in March
March 06, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
February 13, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
January 31, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
January 29, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
January 11, 2024
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
December 26, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
December 13, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
Nanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
December 04, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
November 13, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
November 09, 2023
Conference call and webcast scheduled for Tuesday, November 14, 2023, at 2:00 pm. CET / 8:00 am ET
From
Nanobiotix S.A.
Via
GlobeNewswire
Voting Rights and Shares Capital of the Company
November 08, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Closing of Global Offering
November 07, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
November 02, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
November 01, 2023
From
Nanobiotix S.A.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.